|
1
|
Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival.
|
Blood
|
2003
|
20.10
|
|
2
|
Interleukin-2 and regulatory T cells in graft-versus-host disease.
|
N Engl J Med
|
2011
|
6.02
|
|
3
|
IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo.
|
Blood
|
2006
|
4.46
|
|
4
|
ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death.
|
N Engl J Med
|
2013
|
3.27
|
|
5
|
Rituximab for steroid-refractory chronic graft-versus-host disease.
|
Blood
|
2006
|
3.08
|
|
6
|
Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission.
|
Blood
|
2004
|
2.89
|
|
7
|
Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease.
|
Blood
|
2005
|
2.65
|
|
8
|
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.
|
Proc Natl Acad Sci U S A
|
2009
|
2.54
|
|
9
|
SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice.
|
Blood
|
2006
|
2.53
|
|
10
|
Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease.
|
Blood
|
2009
|
2.50
|
|
11
|
Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation.
|
Blood
|
2011
|
2.41
|
|
12
|
Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans.
|
Blood
|
2011
|
2.33
|
|
13
|
The elusive nature and function of mesenchymal stem cells.
|
Nat Rev Mol Cell Biol
|
2011
|
2.31
|
|
14
|
Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age.
|
Blood
|
2004
|
2.30
|
|
15
|
Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease.
|
Blood
|
2010
|
2.17
|
|
16
|
Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2011
|
2.11
|
|
17
|
Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease.
|
Sci Transl Med
|
2013
|
2.03
|
|
18
|
Gene expression profiles of B-lineage adult acute lymphocytic leukemia reveal genetic patterns that identify lineage derivation and distinct mechanisms of transformation.
|
Clin Cancer Res
|
2005
|
2.02
|
|
19
|
Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation.
|
J Clin Invest
|
2010
|
2.00
|
|
20
|
High levels of B-cell activating factor in patients with active chronic graft-versus-host disease.
|
Clin Cancer Res
|
2007
|
2.00
|
|
21
|
A disease risk index for patients undergoing allogeneic stem cell transplantation.
|
Blood
|
2012
|
2.00
|
|
22
|
Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.
|
Biol Blood Marrow Transplant
|
2006
|
1.99
|
|
23
|
Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia.
|
Blood
|
2005
|
1.89
|
|
24
|
Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis.
|
Blood
|
2010
|
1.88
|
|
25
|
Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation.
|
Biol Blood Marrow Transplant
|
2007
|
1.84
|
|
26
|
Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation.
|
J Exp Med
|
2004
|
1.84
|
|
27
|
Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors.
|
Blood
|
2003
|
1.79
|
|
28
|
Prediction of veno-occlusive disease using biomarkers of endothelial injury.
|
Biol Blood Marrow Transplant
|
2010
|
1.76
|
|
29
|
Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation.
|
Blood
|
2013
|
1.72
|
|
30
|
Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation.
|
J Clin Oncol
|
2012
|
1.68
|
|
31
|
Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion.
|
Blood
|
2013
|
1.67
|
|
32
|
MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma.
|
Proc Natl Acad Sci U S A
|
2008
|
1.59
|
|
33
|
Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation.
|
Am J Hematol
|
2010
|
1.54
|
|
34
|
Viral induction and targeted inhibition of galectin-1 in EBV+ posttransplant lymphoproliferative disorders.
|
Blood
|
2011
|
1.53
|
|
35
|
A modified γ-retrovirus vector for X-linked severe combined immunodeficiency.
|
N Engl J Med
|
2014
|
1.42
|
|
36
|
Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease.
|
Nat Genet
|
2009
|
1.40
|
|
37
|
Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age.
|
Biol Blood Marrow Transplant
|
2010
|
1.39
|
|
38
|
NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction.
|
Biol Blood Marrow Transplant
|
2010
|
1.38
|
|
39
|
Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.
|
J Clin Invest
|
2014
|
1.38
|
|
40
|
Induction of tumor immunity following allogeneic stem cell transplantation.
|
Adv Immunol
|
2006
|
1.35
|
|
41
|
Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.
|
Biol Blood Marrow Transplant
|
2006
|
1.34
|
|
42
|
Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation.
|
Proc Natl Acad Sci U S A
|
2009
|
1.34
|
|
43
|
Probing circulating tumor cells in microfluidics.
|
Lab Chip
|
2013
|
1.34
|
|
44
|
Evidence for ineffective erythropoiesis in severe sickle cell disease.
|
Blood
|
2005
|
1.31
|
|
45
|
Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation.
|
Blood
|
2006
|
1.30
|
|
46
|
Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells.
|
J Clin Invest
|
2013
|
1.30
|
|
47
|
Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
|
Blood
|
2004
|
1.27
|
|
48
|
Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor.
|
Blood
|
2005
|
1.24
|
|
49
|
Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion.
|
Biol Blood Marrow Transplant
|
2002
|
1.23
|
|
50
|
Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2010
|
1.22
|
|
51
|
Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts.
|
Biol Blood Marrow Transplant
|
2011
|
1.19
|
|
52
|
B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways.
|
Blood
|
2012
|
1.15
|
|
53
|
Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial.
|
Blood
|
2013
|
1.14
|
|
54
|
Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors.
|
Blood
|
2009
|
1.12
|
|
55
|
ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction.
|
Proc Natl Acad Sci U S A
|
2002
|
1.12
|
|
56
|
MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells.
|
PLoS One
|
2011
|
1.12
|
|
57
|
Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
|
Clin Cancer Res
|
2004
|
1.11
|
|
58
|
Outcomes of patients with severe combined immunodeficiency treated with hematopoietic stem cell transplantation with and without preconditioning.
|
J Allergy Clin Immunol
|
2009
|
1.09
|
|
59
|
Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens.
|
Blood
|
2003
|
1.09
|
|
60
|
Graft-versus-leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion.
|
Clin Cancer Res
|
2010
|
1.09
|
|
61
|
Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma.
|
Br J Haematol
|
2002
|
1.09
|
|
62
|
Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells.
|
Cancer Res
|
2010
|
1.08
|
|
63
|
Current challenges in chronic graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2009
|
1.06
|
|
64
|
Long-term outcomes of nonconditioned patients with severe combined immunodeficiency transplanted with HLA-identical or haploidentical bone marrow depleted of T cells with anti-CD6 mAb.
|
J Allergy Clin Immunol
|
2008
|
1.06
|
|
65
|
Combined CD4+ donor lymphocyte infusion and low-dose recombinant IL-2 expand FOXP3+ regulatory T cells following allogeneic hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2009
|
1.05
|
|
66
|
Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens.
|
Cancer Res
|
2010
|
1.04
|
|
67
|
Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma.
|
Blood
|
2002
|
1.02
|
|
68
|
A novel rapid single nucleotide polymorphism (SNP)-based method for assessment of hematopoietic chimerism after allogeneic stem cell transplantation.
|
Blood
|
2002
|
1.01
|
|
69
|
Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acid-immunoglobulin complexes in humans.
|
J Clin Invest
|
2011
|
1.01
|
|
70
|
A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2007
|
1.01
|
|
71
|
Early neutrophil engraftment following autologous BMT provides a functional predictor of long-term hematopoietic reconstitution.
|
Transfusion
|
2003
|
0.98
|
|
72
|
Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction.
|
Blood
|
2008
|
0.98
|
|
73
|
Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells.
|
J Clin Invest
|
2012
|
0.98
|
|
74
|
Mixed haematopoietic chimerism for sickle cell disease prevents intravascular haemolysis.
|
Br J Haematol
|
2007
|
0.96
|
|
75
|
A novel mechanism of alternative promoter and splicing regulates the epitope generation of tumor antigen CML66-L.
|
J Immunol
|
2004
|
0.95
|
|
76
|
Up-Regulation of alpha4beta7 integrin on peripheral T cell subsets correlates with the development of acute intestinal graft-versus-host disease following allogeneic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2009
|
0.94
|
|
77
|
Graft-versus-leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells.
|
Clin Cancer Res
|
2005
|
0.93
|
|
78
|
Combined CD4 T-cell and antibody response to human minor histocompatibility antigen DBY after allogeneic stem-cell transplantation.
|
Transplantation
|
2011
|
0.91
|
|
79
|
Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes.
|
Clin Cancer Res
|
2010
|
0.91
|
|
80
|
Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells.
|
Clin Cancer Res
|
2002
|
0.90
|
|
81
|
Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion.
|
Cancer Res
|
2003
|
0.90
|
|
82
|
Bayesian error-in-variable survival model for the analysis of GeneChip arrays.
|
Biometrics
|
2005
|
0.90
|
|
83
|
Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission.
|
Am J Hematol
|
2008
|
0.89
|
|
84
|
Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation.
|
Blood
|
2011
|
0.88
|
|
85
|
Detecting T-cell reactivity to whole cell vaccines: Proof of concept analysis of T-cell response to K562 cell antigens in CML patients.
|
Oncoimmunology
|
2012
|
0.87
|
|
86
|
ZAP-70 expression in acute lymphoblastic leukemia: association with the E2A/PBX1 rearrangement and the pre-B stage of differentiation and prognostic implications.
|
Blood
|
2005
|
0.87
|
|
87
|
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.
|
Cancer Cell
|
2016
|
0.87
|
|
88
|
Human acute stem cell leukemia with multilineage differentiation potential via cascade activation of growth factor receptors.
|
Blood
|
2002
|
0.87
|
|
89
|
Validation of short-term handling and storage conditions for marrow and peripheral blood stem cell products.
|
Transfusion
|
2011
|
0.86
|
|
90
|
Preclinical regulatory validation of a 3-stage amniotic mesenchymal stem cell manufacturing protocol.
|
J Pediatr Surg
|
2008
|
0.85
|
|
91
|
Preclinical regulatory validation of an engineered diaphragmatic tendon made with amniotic mesenchymal stem cells.
|
J Pediatr Surg
|
2011
|
0.85
|
|
92
|
Expression of CD30 in patients with acute graft-versus-host disease.
|
Blood
|
2012
|
0.85
|
|
93
|
Erythroid-lineage-specific engraftment in patients with severe hemoglobinopathy following allogeneic hematopoietic stem cell transplantation.
|
Exp Hematol
|
2008
|
0.84
|
|
94
|
Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosis.
|
Blood
|
2006
|
0.84
|
|
95
|
Targets of tumor immunity after allogeneic hematopoietic stem cell transplantation.
|
Clin Cancer Res
|
2008
|
0.83
|
|
96
|
Identification of cytolytic CD161- CD56+ regulatory CD8 T cells in human peripheral blood.
|
PLoS One
|
2013
|
0.82
|
|
97
|
Characterization of ABL1 expression in adult T-cell acute lymphoblastic leukemia by oligonucleotide array analysis.
|
Haematologica
|
2007
|
0.82
|
|
98
|
Molecular assessment of erythroid lineage chimerism following nonmyeloablative allogeneic stem cell transplantation.
|
Exp Hematol
|
2003
|
0.82
|
|
99
|
Tregs, HSCT, and acute GVHD: up close and personal.
|
Blood
|
2013
|
0.81
|
|
100
|
B-cell-directed therapy for chronic graft-versus-host disease.
|
Haematologica
|
2010
|
0.81
|
|
101
|
Airway dilation in bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation.
|
Respir Med
|
2012
|
0.81
|
|
102
|
Factors associated with bronchiolitis obliterans syndrome and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation.
|
Am J Hematol
|
2014
|
0.81
|
|
103
|
Revealing tumor immunity after hematopoietic stem cell transplantation.
|
Clin Cancer Res
|
2009
|
0.80
|
|
104
|
Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation.
|
Blood
|
2012
|
0.80
|
|
105
|
Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapy.
|
Transfusion
|
2004
|
0.80
|
|
106
|
Allogeneic stem cell transplantation for multiple myeloma.
|
Rev Clin Exp Hematol
|
2002
|
0.80
|
|
107
|
Adult hematopoietic stem cell plasticity.
|
Transfusion
|
2002
|
0.80
|
|
108
|
Sequential infusion of donor-derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantation.
|
Am J Hematol
|
2014
|
0.80
|
|
109
|
FLT3 inhibition in t(4;11)+ adult acute lymphoid leukaemia.
|
Br J Haematol
|
2005
|
0.79
|
|
110
|
White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome.
|
Am J Hematol
|
2014
|
0.79
|
|
111
|
Genomic analysis in lymphoid leukemias.
|
Rev Clin Exp Hematol
|
2005
|
0.78
|
|
112
|
Studying human regulatory T cells in vivo.
|
Clin Cancer Res
|
2006
|
0.78
|
|
113
|
Quantitative monitoring of BCR/ABL transcript during STI-571 therapy.
|
Leuk Lymphoma
|
2002
|
0.78
|
|
114
|
A clonal model for human CD8+ regulatory T cells: unrestricted contact-dependent killing of activated CD4+ T cells.
|
Eur J Immunol
|
2011
|
0.77
|
|
115
|
Synergistic enhancement of cell-mediated immunity by interleukin-12 plus interleukin-2: basis for therapy of cutaneous T cell lymphoma.
|
J Invest Dermatol
|
2002
|
0.77
|
|
116
|
A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
|
Haematologica
|
2013
|
0.76
|
|
117
|
Imatinib therapy for patients with chronic myelogenous leukemia: are patients living longer?
|
Clin Cancer Res
|
2004
|
0.75
|
|
118
|
Time to put the CAR-T before the horse.
|
Blood
|
2011
|
0.75
|
|
119
|
Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2013
|
0.75
|
|
120
|
Development and implementation of a computerized system for collection, processing, and administration of cellular therapy products.
|
J Oncol Pract
|
2012
|
0.75
|